Q1 2025 AGFA Gevaert NV Earnings Call Transcript
Key Points
- Healthcare IT showed an extremely good performance, with a 63% increase in order intake, indicating strong market momentum.
- The company is successfully transitioning to a more recurring revenue business model, particularly in healthcare IT.
- Agfa-Gevaert NV (XBRU:AGFB) has maintained stable adjusted EBITDA despite a challenging market environment, aided by positive exchange rates.
- The company has made significant progress in reducing net pension debt, which has decreased from EUR511 million to below EUR400 million over the past two years.
- Agfa-Gevaert NV (XBRU:AGFB) is actively investing in future growth areas, such as R&D for healthcare IT, and has maintained tight cost controls.
- The company is experiencing a continuous decline in its film business, particularly in China, with a 15% to 16% decrease in volumes.
- There is a weaker investment climate impacting equipment sales in the Digital Print & Chemicals (DPC) segment, leading to delayed investment decisions.
- The radiology market is facing a more pronounced decline than anticipated, affecting overall sales and profitability.
- Agfa-Gevaert NV (XBRU:AGFB) is consuming EUR27 million in cash flow in Q1 due to seasonality and increased working capital.
- The company is facing challenges in the green hydrogen market, with delays in project implementations and a changing industry structure.
Hello and welcome to the AGFA Group Q1 2025 results. My name is Laura, and I will be a coordinator for today's event. (Operator Instructions)
I will now hand you over to your host, Pascal Juery, CEO to begin today's conference. Thank you.
Thank you very much, Laura. Good morning to everyone. I'm sitting in Mortsel, with, Fiona Lam, our CFO, with Viviane Dictus, our Investment Relations Manager, and the rest of the executive committee, ready to answer your question. So, we're going to walk you through the Q1, results of, the company and with further do.
Will start, so Q1, stably [EBITDA] compared to last year but with a very different, sales and activity mix, and in fact, this is a story of, on the one side the continuous decline of the film which, as has started to accelerate in '24 and we are seeing this trend continuing of course in '25. On the other hand, a good performance of the growth engines and I would say a good cost control
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
